Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

被引：15
|
作者：
Verstovsek, Srdan
Deeg, H. Joachim [3 ]
Odenike, Olatoyosi [4 ]
Zhu, Joy [5 ]
Kantarjian, Hagop [1 ]
Estrov, Zeev
Scott, Bart Lee [2 ]
Thomas, Deborah A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Fred Hutchinson Canc Res Ctr, Dept Clin Res, Seattle, WA 98104 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] S BIO, Global Clin Dev, Redwood City, CA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
10.1182/blood.V116.21.3082.3082
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1271 / 1271
页数：1
相关论文
共 50 条
  • [21] The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
    Novotny-Diermayr, V.
    Hart, S.
    Goh, K. C.
    Cheong, A.
    Ong, L-C
    Hentze, H.
    Pasha, M. K.
    Jayaraman, R.
    Ethirajulu, K.
    Wood, J. M.
    BLOOD CANCER JOURNAL, 2012, 2 : e69 - e69
  • [22] The Effects of SB1518, a Novel Oral JAK2 Inhibitor, On Ex Vivo Expanded PV Erythroid Progenitors Correlate with Clinical Observations
    Goh, Kee Chuan
    Hart, Stefan
    Tan, Yong Cheng
    Chithra, Amalini
    Ong, Kiat H.
    Wood, Jeanette
    BLOOD, 2009, 114 (22) : 1138 - 1138
  • [23] Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor
    Lou, Yin-jun
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (02) : 212 - 213
  • [24] Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor
    Yin-jun Lou
    Acta Pharmacologica Sinica, 2012, 33 : 212 - 213
  • [25] Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma.
    Hart, Stefan
    Goh, Kee Chuan
    Tan, Yong Cheng
    Chithra, Amalini
    Wood, Jeanette
    BLOOD, 2009, 114 (22) : 750 - 750
  • [26] PACRITINIB Inhibitor of Tyrosine-Protein Kinase JAK2 Inhibitor of FLT-3 Treatment of Myelofibrosis
    Verstovsek, S.
    Machida, C.
    Dean, J. P.
    Myint, H.
    DRUGS OF THE FUTURE, 2013, 38 (06) : 375 - 386
  • [27] JAK2 inhibitor treatment of anemia in myelofibrosis
    Tefferi, Ayalew
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : 995 - 997
  • [28] Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity
    Younes, Anas
    Fanale, Michelle
    McLaughlin, Peter
    Copeland, Amanda R.
    Faria, Silvana de Castro
    Wood, Jeanette
    Ethirajulu, Kantharaj
    Zhu, Huan J.
    BLOOD, 2009, 114 (22) : 244 - 244
  • [29] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [30] Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms
    Hu, Mengshi
    Yang, Tao
    Yang, Linyu
    Niu, Lu
    Zhu, Jinbing
    Zhao, Ailin
    Shi, Mingsong
    Yuan, Xue
    Tang, Minghai
    Yang, Jianhong
    Pei, Heying
    Yang, Zhuang
    Chen, Qiang
    Ye, Haoyu
    Niu, Ting
    Chen, Lijuan
    BLOOD CANCER JOURNAL, 2022, 12 (03)
12345